#USA #San Rafael #BioMarin #VOXZOGO #achondroplasia

BioMarin Unveils Groundbreaking Data on Achondroplasia Treatment

BioMarin Pharmaceutical Inc. recently announced it will present exciting findings from 13 pivotal studies at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting, taking place in Boston. This announcement comes as a significant step forward in advancing treatment options for two skeletal dysplasias: achondroplasia and hypochondroplasia.

Key Highlights of the Presentation

At the meeting, BioMarin's research team will showcase new imaging results derived from a post-hoc analysis of a double-blind, placebo-controlled trial, which evaluates the effects of their drug, VOXZOGO® (vosoritide), on the growth of the foramen magnum and the craniocervical junction in children with achondroplasia.

Dr. Greg Friberg, the Executive Vice President and Chief Research Development Officer at BioMarin, noted that these findings provide valuable insights into how VOXZOGO can potentially influence critical areas of the skull, which are often implicated in severe complications such as cervicomedullary compression.

VOXZOGO: A Game Changer

What makes VOXZOGO particularly promising is its application in infants and young children. The early administration of this treatment is emphasized as it can have a more profound impact on growth. Accompanying this data, BioMarin will also share findings related to bone strength, limb alignment, and ongoing efforts regarding hypochondroplasia, including research into the next-generation drug BMN 333.

Regulatory Updates

BioMarin is actively pursuing regulatory approval for VOXZOGO as a treatment for hypochondroplasia with a recently submitted supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA). If approved, this would be the first targeted therapy available for treat hypochondroplasia, potentially launching in 2027. The company is also on track with submissions to the European Medicines Agency (EMA) and other health authorities.

Presentation Breakdown

Key presentations scheduled at ASBMR include:
1. C-Type Natriuretic Peptide Agonist CNP38 - An oral presentation that discusses its role in promoting longitudinal bone growth. Scheduled for October 12.
2. BMN 333 - Illustrated through a poster presentation, this investigational product is designed to promote endochondral bone growth.
3. Vosoritide’s Impact on Bone Strength - This poster presentation will explore the drug's effects in children diagnosed with achondroplasia.
4. Efficacy of BMN 401 - Demonstrating results from the Phase 3 ENERGY 3 study in children with ENPP1 deficiency.
5. Research on Hypophosphatasia - Reviewing the economic burden and existing treatment gaps in patients diagnosed with this condition.

Understanding Achondroplasia and Hypochondroplasia

Achondroplasia is recognized as the most prevalent form of skeletal dysplasia, leading to disproportionate short stature in humans, while hypochondroplasia involves impaired bone growth, presenting significant challenges for affected individuals. BioMarin estimates that around 14,000 children with hypochondroplasia might be eligible for VOXZOGO therapy, highlighting the urgent need for effective treatments.

Conclusion

BioMarin's commitment to improving the lives of children suffering from skeletal dysplasias is clear through its continuous research efforts. As they unveil new data and share promising developments at the ASBMR meeting, the focus is not only on immediate impact through treatments like VOXZOGO but also on future innovations like BMN 333. The implications of this research reach far beyond the conference room, bringing hope to families navigating the complexities of these conditions.

For further details about clinical trials and ongoing research related to achondroplasia and hypochondroplasia, interested parties are directed to visit BioMarin's dedicated clinical trials website.